Overview

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to assess the safety of Mylotarg therapy in routine practice.
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Gemtuzumab